Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Feedback activation of NF-KB signaling leads to adaptive resistance to EZH2 inhibitors in prostate cancer cells
Authors
Keywords
-
Journal
Cancer Cell International
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-02
DOI
10.1186/s12935-021-01897-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EZH2: a novel target for cancer treatment
- (2020) Ran Duan et al. Journal of Hematology & Oncology
- NF-κB signaling promotes castration-resistant prostate cancer initiation and progression
- (2020) Shayna E. Thomas-Jardin et al. PHARMACOLOGY & THERAPEUTICS
- The role of SOX family members in solid tumours and metastasis
- (2019) Daniela Grimm et al. SEMINARS IN CANCER BIOLOGY
- Inhibition of EZH2 ameliorates cartilage endplate degeneration and attenuates the progression of intervertebral disc degeneration via demethylation of Sox-9
- (2019) Chao Jiang et al. EBioMedicine
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer incidence and mortality in China, 2014
- (2018) Wanqing Chen et al. Chinese Journal of Cancer Research
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
- (2018) Elizabeth Ahern et al. Nature Reviews Clinical Oncology
- Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
- (2018) Jung Kim et al. Cell Reports
- S-adenosylhomocysteine induces inflammation through NFkB: A possible role for EZH2 in endothelial cell activation
- (2016) Madalena Barroso et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- SOX9 drives WNT pathway activation in prostate cancer
- (2016) Fen Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
- (2016) Raushan T. Kurmasheva et al. PEDIATRIC BLOOD & CANCER
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Multifaceted role of EZH2 in breast and prostate tumorigenesis
- (2013) Gauri Deb et al. Epigenetics
- The complexity of NF-κB signaling in inflammation and cancer
- (2013) Bastian Hoesel et al. Molecular Cancer
- PRC2 directly methylates GATA4 and represses its transcriptional activity
- (2012) A. He et al. GENES & DEVELOPMENT
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SOX9 Elevation in the Prostate Promotes Proliferation and Cooperates with PTEN Loss to Drive Tumor Formation
- (2010) M. K. Thomsen et al. CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started